RECORD // Company

uniQure N.V.

Formerly: uniQure B.V.

Built 2026-11-21T11:38:40Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • UniQure N.V. · Ctgov · same registered legal name as 'uniQure N.V.' Possible match based on name, not a shared identifier. Compare the records. Compare

9 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001104659-26-122367

ItemValuePeriodFormFiledAccessionReport
Revenue$5,196,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223672026-11-21 11:38 UTCReport an error
Net income (loss)$-61,217,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223672026-11-21 11:38 UTCReport an error
Interest expense$14,576,0003 months ended 2026-09-3010-Q2026-11-040001104659-26-1223672026-11-21 11:38 UTCReport an error
Cash and cash equivalents$98,442,000at 2026-09-3010-Q2026-11-040001104659-26-1223672026-11-21 11:38 UTCReport an error
Debt due in the next 12 months (from an earlier report)$4,791,000at 2025-12-3110-K2026-03-020001104659-26-0218982026-11-21 11:38 UTCReport an error
Debt due in year 2 (from an earlier report)$5,416,000at 2025-12-3110-K2026-03-020001104659-26-0218982026-11-21 11:38 UTCReport an error
Debt due in year 3 (from an earlier report)$10,243,000at 2025-12-3110-K2026-03-020001104659-26-0218982026-11-21 11:38 UTCReport an error
Debt due in year 4 (from an earlier report)$26,534,000at 2025-12-3110-K2026-03-020001104659-26-0218982026-11-21 11:38 UTCReport an error
Debt due in year 5 (from an earlier report)$24,938,000at 2025-12-3110-K2026-03-020001104659-26-0218982026-11-21 11:38 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001590560
Ticker
QURE
CUSIP
N90064101
Record ID
sx:sec:0001590560

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

29 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-10SEC EDGAR company profile2026-11-21 11:38 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-10SEC EDGAR company profile2026-11-21 11:38 UTCReport an error
Fiscal year end (MMDD)12312026-11-10SEC EDGAR company profile2026-11-21 11:38 UTCReport an error
Business addressPAASHEUVELWEG 25A, AMSTERDAM, 1105 BP2026-11-10SEC EDGAR company profile2026-11-21 11:38 UTCReport an error
ExchangesNasdaq2026-11-10SEC EDGAR company profile2026-11-21 11:38 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$16,098,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-21 11:38 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-198,971,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:38 UTCReport an error
Total assets (at 2025-12-31)$824,908,0002025-12-3110-K, XBRL Assets2026-11-21 11:38 UTCReport an error
Stockholders' equity (at 2025-12-31)$198,901,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:38 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$80,240,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:38 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-177,963,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:38 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$439,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:38 UTCReport an error
Long-term debt (at 2025-12-31)$71,922,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 11:38 UTCReport an error
Operating lease liabilities (at 2025-12-31)$13,694,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:38 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 2.02, including the accompanying Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company…2026-11-04SEC EDGAR 8-K 0001104659-26-122362 (text as filed, excerpt)2026-11-21 11:38 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-02)On November 2, 2026, uniQure N.V. (the “Company”) issued a press release announcing the U.S. Food and Drug Administration (“FDA”) has accepted for review the Biologics License Application (“BLA”) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The information provided in this Item 7.01, including the accompanying Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference…2026-11-02SEC EDGAR 8-K 0001104659-26-120915 (text as filed, excerpt)2026-11-21 11:38 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-02)On November 2, 2026, the Company announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of May 1, 2027. In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting. The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external…2026-11-02SEC EDGAR 8-K 0001104659-26-120915 (text as filed, excerpt)2026-11-21 11:38 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-29)On September 29, 2026, uniQure N.V. (the “Company”) presented an update of its ongoing clinical trials of AMT-130 (the “Presentation”) and issued a press release which summarizes the Presentation (the “Release”). Copies of the Presentation and Release are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated into this Item 7.01 by reference. The information in this Item 7.01 of this Current Report on Form 8-K, the Presentation and the Release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of…2026-09-29SEC EDGAR 8-K 0001104659-26-111654 (text as filed, excerpt)2026-11-21 11:38 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-02)On September 2, 2026, uniQure N.V. (the “Company”) issued a press release announcing the submission of a Biologics License Application to the United States Food and Drug Administration for the accelerated approval of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington’s disease, as well as the submission of a Marketing Authorisation Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency for ifezuntirgene inilparvovec for the treatment of Huntington’s disease. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01…2026-09-02SEC EDGAR 8-K 0001104659-26-104463 (text as filed, excerpt)2026-11-21 11:38 UTCReport an error
Largest institutional holder #1 (13F as filed): Avoro Capital Advisors LLC$309,881,4092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #2 (13F as filed): JPMORGAN CHASE & CO$230,813,2502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #3 (13F as filed): RTW INVESTMENTS, LP$181,548,8062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #4 (13F as filed): STATE STREET CORP$133,750,1802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #5 (13F as filed): Aberdeen Group plc$131,184,2692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #6 (13F as filed): BlackRock, Inc.$86,475,4842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #7 (13F as filed): ORBIMED ADVISORS LLC$83,252,8052026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #8 (13F as filed): JANE STREET GROUP, LLC$74,178,8472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #9 (13F as filed): JENNISON ASSOCIATES LLC$71,918,6362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error
Largest institutional holder #10 (13F as filed): Boxer Capital Management, LLC$69,241,9982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:38 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.